Researchers have developed the most comprehensive atlas linking plasma proteins to diseases and traits in over 53,000 individuals, offering groundbreaking insights for precision medicine. This resource uncovers 168,100 protein-disease associations and identifies new therapeutic targets.
Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns
Share this article Eli Lilly said the FDA wants the AdCom to better understand efficacy implications of its unique trial design. Image credit: Shutterstock /